Skip to main content

Table 9 24-h ambulatory blood pressure on treatment with placebo and different daily doses of rostafuroxin in previously untreated patients

From: Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin

  

Mean level ± SD

at end of treatment period

Mean difference

(95% CI)

P-values

 

N

Placebo

Rostafuroxin

Rostafuroxin minus

placebo

Treatment

effect

Carryover

effect

Period

effect

Systolic pressure, mm Hg

      

   0.05 mg

55

131.9 ± 10.7

133.9 ± 11.5

2.02 (-0.68 to 4.73)

0.139

0.129

0.282

   0.15 mg

39

130.9 ± 10.7

131.5 ± 11.8

0.51 (-2.59 to 3.60)

0.743

0.179

0.588

   0.5 mg

36

135.2 ± 9.5

135.2 ± 9.4

0.04 (-3.38 to 3.46)

0.981

0.523

0.815

   1.5 mg

40

135.3 ± 14.0

137.7 ± 11.7

2.39 (-1.20 to 5.99)

0.185

0.975

0.193

   5.0 mg

44

133.7 ± 10.5

133.0 ± 12.2

-0.68 (-3.72 to 2.36)

0.654

0.831

0.749

   All doses

214

133.3 ± 11.2

134.2 ± 11.5

0.91 (-0.45 to 2.28)

0.188

0.598

0.911

Diastolic pressure, mm Hg

      

   0.05 mg

55

80.4 ± 7.4

81.9 ± 7.8

1.53 (-0.22 to 3.28)

0.085

0.238

0.436

   0.15 mg

39

81.9 ± 7.6

81.5 ± 8.1

-0.42(-2.80 to 1.97)

0.725

0.952

0.328

   0.5 mg

36

85.6 ± 7.8

84.2 ± 9.1

-1.42(-3.77 to 0.94)

0.230

0.803

0.739

   1.5 mg

40

82.5 ± 9.5

84.0 ± 7.7

1.52 (-0.42 to 3.47)

0.121

0.667

0.463

   5.0 mg

44

82.4 ± 7.4

82.2 ± 6.9

-0.16 (-2.07 to 1.75)

0.867

0.719

0.927

   All doses

214

82.4 ± 8.0

82.7 ± 7.9

0.32 (-0.57 to 1.22)

0.474

0.405

0.757

  1. Mean differences were estimated using analysis of variance with sequence, subjects nested within sequence, and period and treatment group entered as covariables. Abbreviations: CI, confidence interval; N = number of patients; SD, standard deviation.